RxDoctor Payments DataLook up a doctor →

Christopher Lynn, MD

Neurology · Hattiesburg, MSNPI 1386759603

Payments from drug & device makers

$20,177in general payments, 2019–2025

Across 1,145 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Acadia Pharmaceuticals Inc$1K
  • Eisai Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$962
  • AstraZeneca$899
  • UCB, Inc.$893
  • plus $13K from 52 others

What the payments were for

  • Speaking & faculty fees$1281%
  • Food & beverage$19,94899%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)163$2,359
Acadia Pharmaceuticals Inc71$1,280
Eisai Inc.56$1,124
Teva Pharmaceuticals USA, Inc.59$962
AstraZeneca(2 entities)39$899
UCB, Inc.49$893
Novartis58$843
Neurocrine Biosciences, Inc.36$761
Argenx US, Inc.31$729
SK Life Science, Inc.28$723
Pfizer63$722
MDD US Operations, LLC18$713
EMD Serono, Inc.37$597
Bristol Myers Squibb32$569
Sunovion Pharmaceuticals Inc.37$566
Lilly USA, LLC36$563
Lundbeck LLC30$547
Genentech USA, Inc.32$497
Sanofi24$497
Biogen26$432
Amgen(2 entities)24$405
Acorda Therapeutics, Inc20$375
TG Therapeutics, Inc.16$303
Merz Pharmaceuticals, LLC13$287
ANI Pharmaceuticals, Inc.14$255
Otsuka America Pharmaceutical, Inc.7$162
Supernus Pharmaceuticals, Inc.9$153
Impel Pharmaceuticals Inc.9$142
Avanir Pharmaceuticals, Inc.8$127
GE HealthCare7$123
Kyowa Kirin, Inc.7$122
Biohaven Pharmaceutical Holding Company Ltd.11$121
Jazz Pharmaceuticals Inc.5$118
Biohaven Pharmaceuticals, Inc.10$113
Octapharma USA, Inc.5$111
Sumitomo Pharma America, Inc.6$93
Grifols USA, LLC4$91
Daiichi Sankyo Inc.4$81
Vanda Pharmaceuticals Inc.4$77
Alnylam Pharmaceuticals Inc.4$76
Upsher-smith Laboratories LLC5$70
Amneal Pharmaceuticals LLC4$61
Tanabe Pharma America, Inc.3$50
Neurelis, Inc.2$49
Greenwich Biosciences, Inc.2$36
Catalyst Pharmaceuticals, Inc.2$35
Adamas Pharmaceuticals, Inc.2$33
Medtronic2$31
Mallinckrodt Enterprises LLC2$28
Axsome Therapeutics, Inc.1$26
Ultragenyx Pharmaceutical Inc.1$24
Promius Pharma LLC1$23
Otsuka Pharmaceutical Development & Commercialization, Inc.1$22
Immedica Pharma US, Inc.1$19
Arbor Pharmaceuticals, Inc.1$19
Averitas Pharma Inc.1$16
Johnson & Johnson1$13
Assertio Therapeutics, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,177 in reported general payments places this provider in the 75th percentile of 111 neurology providers in Mississippi.

See all neurology providers in Mississippi

Medicare billing

Part B allowed, 2024
$1,327,737
Medicare patients
980
Services billed
203,099

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4625$165,336
AustedoDeutetrabenazine14$133,199
VumerityDiroximel Fumarate12$112,137
AptiomEslicarbazepine Acetate21$42,876
Aimovig AutoinjectorErenumab-Aooe46$40,339
Nurtec OdtRimegepant Sulfate14$13,600
FycompaPerampanel11$12,762
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone35$12,497
Carbidopa-LevodopaCarbidopa/Levodopa315$10,167
Levetiracetam423$8,474
Memantine Hcl395$6,719
Gabapentin346$5,542
Pregabalin242$4,824
Topiramate374$4,403
Lacosamide54$3,891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$91$165,33625 claims
Teva Pharmaceuticals USA, Inc.Austedo$962$133,19914 claims
BiogenVumerity$432$112,13712 claims
Sunovion Pharmaceuticals Inc.Aptiom$566$42,87621 claims
PfizerNurtec Odt$722$13,60014 claims
Eisai Inc.Fycompa$1,124$12,76211 claims
Upsher-smith Laboratories LLCTopiramate$70$4,403374 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 111 neurology providers in Mississippi.

Other neurology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →